SCHEMBL704433

SCHEMBL704433

CSc1csc(NC(=O)c2ccc(OC(C)=O)cc2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.58
HSD17B10 Q99714 1/20 0.58
MAPT P10636 4/20 0.51
NPC1 O15118 6/20 0.50
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 3/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50
ADORA3 P0DMS8 3/20 0.48
MAPK1 P28482 2/20 0.46
HSP90AA1 P07900 1/20 0.46
F2 P00734 1/20 0.46
TSHR P16473 1/20 0.46
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL702035 0.86 NPC1 (0.57) RAB9AMAPTNPC1KMT2AMEN1
SCHEMBL4757975 0.81 NPC1 (0.67) RAB9AHSD17B10MAPTNPC1KMT2A
SCHEMBL13055749 0.79 RAB9A (0.57) RAB9AHSD17B10MAPTNPC1KMT2A
SCHEMBL705314 0.79 RAB9A (0.57) RAB9AHSD17B10MAPTNPC1KMT2A
SCHEMBL705399 0.78 RAB9A (0.51) RAB9AHSD17B10MAPTNPC1KMT2A
SCHEMBL2696751 0.78 RAB9A (0.56) RAB9AHSD17B10MAPTNPC1KMT2A
SCHEMBL13055751 0.75 RAB9A (0.53) RAB9AHSD17B10MAPTNPC1KMT2A
SCHEMBL705577 0.75 RAB9A (0.58) RAB9AHSD17B10MAPTNPC1KMT2A
SCHEMBL704410 0.72 L3MBTL1 (0.45) RAB9AHSD17B10MAPTNPC1KMT2A
SCHEMBL24242616 0.70 NPC1 (0.69) RAB9AHSD17B10MAPTNPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11850237-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2023-12-26 US disclosed
US-11850237-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2023-12-26 US disclosed
EP-2445349-B1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES LC (US) 2022-02-09 EP disclosed
EP-3895706-A1 THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS Romark Laboratories, L.C. (US) 2021-10-20 EP disclosed
US-20210177809-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2021-06-17 US disclosed
US-10912768-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2021-02-09 US disclosed
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2019-10-10 US disclosed
US-10363243-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2019-07-30 US disclosed
US-20180078533-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2018-03-22 US disclosed
US-20180078533-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2018-03-22 US disclosed
US-20120122939-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES, L.C. 2012-05-17 US disclosed
US-20120108591-A1 ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES, L.C. 2012-05-03 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. 2010-12-30 US disclosed
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. 2010-12-30 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10912768-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 RAB9A 1890/4885HSD17B10 1673/4885MAPT 3766/4885
US-20180078533-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 RAB9A 1890/4885HSD17B10 1673/4885MAPT 3766/4885
US-20210177809-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 RAB9A 1890/4885HSD17B10 1673/4885MAPT 3766/4885
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 RAB9A 1890/4885HSD17B10 1673/4885MAPT 3766/4885
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 RAB9A 1890/4885HSD17B10 1673/4885MAPT 3766/4885
US-11850237-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 RAB9A 1890/4885HSD17B10 1673/4885MAPT 3766/4885
US-20120108591-A1 ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, HCCS RAB9A 1584/4885HSD17B10 626/4885MAPT 4209/4885
US-20120122939-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC RAB9A 1694/4885HSD17B10 921/4885MAPT 4288/4885
US-10363243-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 RAB9A 1890/4885HSD17B10 1673/4885MAPT 3766/4885
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC RAB9A 1694/4885HSD17B10 921/4885MAPT 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.